Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 186

1.

Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-AS.

Saintas E, Abrahams L, Ahmad GT, Ajakaiye AM, AlHumaidi AS, Ashmore-Harris C, Clark I, Dura UK, Fixmer CN, Ike-Morris C, Mato Prado M, Mccullough D, Mishra S, Schöler KM, Timur H, Williamson MD, Alatsatianos M, Bahsoun B, Blackburn E, Hogwood CE, Lithgow PE, Rowe M, Yiangou L, Rothweiler F, Cinatl J Jr, Zehner R, Baines AJ, Garrett MD, Gourlay CW, Griffin DK, Gullick WJ, Hargreaves E, Howard MJ, Lloyd DR, Rossman JS, Smales CM, Tsaousis AD, von der Haar T, Wass MN, Michaelis M.

PLoS One. 2017 Feb 13;12(2):e0172140. doi: 10.1371/journal.pone.0172140. eCollection 2017.

2.

The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility.

Kiuchi T, Ortiz-Zapater E, Monypenny J, Matthews DR, Nguyen LK, Barbeau J, Coban O, Lawler K, Burford B, Rolfe DJ, de Rinaldis E, Dafou D, Simpson MA, Woodman N, Pinder S, Gillett CE, Devauges V, Poland SP, Fruhwirth G, Marra P, Boersma YL, Plückthun A, Gullick WJ, Yarden Y, Santis G, Winn M, Kholodenko BN, Martin-Fernandez ML, Parker P, Tutt A, Ameer-Beg SM, Ng T.

Sci Signal. 2014 Aug 19;7(339):ra78. doi: 10.1126/scisignal.2005157.

PMID:
25140053
3.

Brown and white adipose tissues: intrinsic differences in gene expression and response to cold exposure in mice.

Rosell M, Kaforou M, Frontini A, Okolo A, Chan YW, Nikolopoulou E, Millership S, Fenech ME, MacIntyre D, Turner JO, Moore JD, Blackburn E, Gullick WJ, Cinti S, Montana G, Parker MG, Christian M.

Am J Physiol Endocrinol Metab. 2014 Apr 15;306(8):E945-64. doi: 10.1152/ajpendo.00473.2013. Epub 2014 Feb 18.

4.

The neuregulin system of ligands and their receptors in rat islets of langerhans.

South JC, Blackburn E, Brown IR, Gullick WJ.

Endocrinology. 2013 Jul;154(7):2385-92. doi: 10.1210/en.2012-2133. Epub 2013 Apr 22.

PMID:
23610133
5.

A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines.

Blackburn E, Zona S, Murphy ML, Brown IR, Chan SK, Gullick WJ.

Breast Cancer Res Treat. 2012 Jul;134(1):53-9. doi: 10.1007/s10549-011-1908-1. Epub 2011 Dec 15.

PMID:
22169894
6.

Localisation of Neuregulin 1-β3 to different sub-nuclear structures alters gene expression.

Wang M, Trim CM, Gullick WJ.

Exp Cell Res. 2011 Feb 15;317(4):423-32. doi: 10.1016/j.yexcr.2010.11.009. Epub 2010 Nov 24.

PMID:
21110958
7.

Expression of neuregulin 4 splice variants in normal human tissues and prostate cancer and their effects on cell motility.

Hayes NV, Blackburn E, Boyle MM, Russell GA, Frost TM, Morgan BJ, Gullick WJ.

Endocr Relat Cancer. 2010 Dec 13;18(1):39-49. doi: 10.1677/ERC-10-0112. Print 2011 Feb.

PMID:
20959441
8.

The epidermal growth factor system of ligands and receptors in cancer.

Gullick WJ.

Eur J Cancer. 2009 Sep;45 Suppl 1:205-10. doi: 10.1016/S0959-8049(09)70035-8. Review. No abstract available.

PMID:
19775619
9.

The complete family of epidermal growth factor receptors and their ligands are co-ordinately expressed in breast cancer.

McIntyre E, Blackburn E, Brown PJ, Johnson CG, Gullick WJ.

Breast Cancer Res Treat. 2010 Jul;122(1):105-10. doi: 10.1007/s10549-009-0536-5. Epub 2009 Sep 17.

PMID:
19760033
10.

The epidermal growth factor family of ligands and receptors grows and grows.

Gullick WJ, Jones FE.

J Mammary Gland Biol Neoplasia. 2008 Jun;13(2):157. doi: 10.1007/s10911-008-9085-5. Epub 2008 May 8. No abstract available.

PMID:
18463793
11.

The neuregulin family of genes and their multiple splice variants in breast cancer.

Hayes NV, Gullick WJ.

J Mammary Gland Biol Neoplasia. 2008 Jun;13(2):205-14. doi: 10.1007/s10911-008-9078-4. Epub 2008 Apr 15. Review.

PMID:
18415007
12.

Characterization of the cell membrane-associated products of the Neuregulin 4 gene.

Hayes NV, Newsam RJ, Baines AJ, Gullick WJ.

Oncogene. 2008 Jan 24;27(5):715-20. Epub 2007 Aug 6.

PMID:
17684490
13.

Identification and characterization of novel spliced variants of neuregulin 4 in prostate cancer.

Hayes NV, Blackburn E, Smart LV, Boyle MM, Russell GA, Frost TM, Morgan BJ, Baines AJ, Gullick WJ.

Clin Cancer Res. 2007 Jun 1;13(11):3147-55.

14.

Proteomic identification of secreted proteins as surrogate markers for signal transduction inhibitor activity.

McClelland CM, Gullick WJ.

Br J Cancer. 2007 Jan 29;96(2):284-9. Epub 2007 Jan 9.

15.

The role of the epidermal growth factor receptor in breast cancer.

Chan SK, Hill ME, Gullick WJ.

J Mammary Gland Biol Neoplasia. 2006 Jan;11(1):3-11. Review.

PMID:
16947082
17.

Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy.

Chan SK, Gullick WJ, Hill ME.

Eur J Cancer. 2006 Jan;42(1):17-23. Review.

PMID:
16364841
18.

Neuregulins 1-4 are expressed in the cytoplasm or nuclei of ductal carcinoma (in situ) of the human breast.

Marshall C, Blackburn E, Clark M, Humphreys S, Gullick WJ.

Breast Cancer Res Treat. 2006 Mar;96(2):163-8. Epub 2005 Oct 27.

PMID:
16261396
19.

Clinical value of epidermal growth factor receptor expression in primary breast cancer.

Rampaul RS, Pinder SE, Nicholson RI, Gullick WJ, Robertson JF, Ellis IO.

Adv Anat Pathol. 2005 Sep;12(5):271-3. Review.

PMID:
16210923
20.

The epidermal growth factor receptor family.

Bazley LA, Gullick WJ.

Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S17-27. Review.

PMID:
16113093
21.

Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment.

Gee JM, Howell A, Gullick WJ, Benz CC, Sutherland RL, Santen RJ, Martin LA, Ciardiello F, Miller WR, Dowsett M, Barrett-Lee P, Robertson JF, Johnston SR, Jones HE, Wakeling AE, Duncan R, Nicholson RI.

Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S1-7. Review.

PMID:
16113086
22.

Heparin-binding epidermal growth factor and its receptors mediate decidualization and potentiate survival of human endometrial stromal cells.

Chobotova K, Karpovich N, Carver J, Manek S, Gullick WJ, Barlow DH, Mardon HJ.

J Clin Endocrinol Metab. 2005 Feb;90(2):913-9. Epub 2004 Nov 23.

23.

A recurrent chromosome breakpoint in breast cancer at the NRG1/neuregulin 1/heregulin gene.

Huang HE, Chin SF, Ginestier C, Bardou VJ, Adélaïde J, Iyer NG, Garcia MJ, Pole JC, Callagy GM, Hewitt SM, Gullick WJ, Jacquemier J, Caldas C, Chaffanet M, Birnbaum D, Edwards PA.

Cancer Res. 2004 Oct 1;64(19):6840-4.

24.

Mapping nucleolar and spliceosome localization sequences of neuregulin1-beta3.

Golding M, Ruhrberg C, Sandle J, Gullick WJ.

Exp Cell Res. 2004 Sep 10;299(1):110-8.

PMID:
15302578
25.

Simulating complex intracellular processes using object-oriented computational modelling.

Johnson CG, Goldman JP, Gullick WJ.

Prog Biophys Mol Biol. 2004 Nov;86(3):379-406. Review.

PMID:
15302205
26.

Targeted radiosensitisation by pegylated liposome-encapsulated 3', 5'-O-dipalmitoyl 5-iodo-2'-deoxyuridine in a head and neck cancer xenograft model.

Harrington KJ, Syrigos KN, Uster PS, Zetter A, Lewanski CR, Gullick WJ, Vile RG, Stewart JS.

Br J Cancer. 2004 Jul 19;91(2):366-73.

27.

Co-expression of neuregulins 1, 2, 3 and 4 in human breast cancer.

Dunn M, Sinha P, Campbell R, Blackburn E, Levinson N, Rampaul R, Bates T, Humphreys S, Gullick WJ.

J Pathol. 2004 Jun;203(2):672-80.

PMID:
15141382
28.

Neuregulin 1-alpha expression in locally advanced breast cancer.

Raj EH, Skinner A, Mahji U, Nirmala KN, Ravichandran K, Shanta V, Hurst HC, Gullick WJ, Rajkumar T.

Breast. 2001 Feb;10(1):41-5.

PMID:
14965558
29.

Identification of surrogate markers for determining drug activity using proteomics.

McClelland CM, Gullick WJ.

Biochem Soc Trans. 2003 Dec;31(Pt 6):1488-90. Review.

PMID:
14641096
30.

c-erbB-4/HER4: friend or foe?

Gullick WJ.

J Pathol. 2003 Jul;200(3):279-81.

PMID:
12845622
31.

Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4.

Lodge AJ, Anderson JJ, Gullick WJ, Haugk B, Leonard RC, Angus B.

J Clin Pathol. 2003 Apr;56(4):300-4.

32.

A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor.

Jungbluth AA, Stockert E, Huang HJ, Collins VP, Coplan K, Iversen K, Kolb D, Johns TJ, Scott AM, Gullick WJ, Ritter G, Cohen L, Scanlan MJ, Cavenee WK, Old LJ.

Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):639-44. Epub 2003 Jan 6. Erratum in: Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2163. Cavanee, Webster K [corrected to Cavenee, Webster K].

33.

Neuregulin expression, function, and signaling in human ovarian cancer cells.

Gilmour LM, Macleod KG, McCaig A, Sewell JM, Gullick WJ, Smyth JF, Langdon SP.

Clin Cancer Res. 2002 Dec;8(12):3933-42.

34.

The mitogenic potential of heparin-binding epidermal growth factor in the human endometrium is mediated by the epidermal growth factor receptor and is modulated by tumor necrosis factor-alpha.

Chobotova K, Muchmore ME, Carver J, Yoo HJ, Manek S, Gullick WJ, Barlow DH, Mardon HJ.

J Clin Endocrinol Metab. 2002 Dec;87(12):5769-77.

35.

Heparin-binding epidermal growth factor and its receptor ErbB4 mediate implantation of the human blastocyst.

Chobotova K, Spyropoulou I, Carver J, Manek S, Heath JK, Gullick WJ, Barlow DH, Sargent IL, Mardon HJ.

Mech Dev. 2002 Dec;119(2):137-44.

36.

Transforming growth factor alpha, amphiregulin and cripto-1 are frequently expressed in advanced human ovarian carcinomas.

D'Antonio A, Losito S, Pignata S, Grassi M, Perrone F, De Luca A, Tambaro R, Bianco C, Gullick WJ, Johnson GR, Iaffaioli VR, Salomon DS, Normanno N.

Int J Oncol. 2002 Nov;21(5):941-8.

PMID:
12370739
37.

HER-2 in breast cancer--methods of detection, clinical significance and future prospects for treatment.

Rampaul RS, Pinder SE, Gullick WJ, Robertson JF, Ellis IO.

Crit Rev Oncol Hematol. 2002 Sep;43(3):231-44. Review.

PMID:
12270780
38.

A new model for ductal carcinoma in situ suggests strategies for treatment.

Gullick WJ.

Breast Cancer Res. 2002;4(5):176-8. Epub 2002 Jul 19. Review.

39.

Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene.

Johns TG, Stockert E, Ritter G, Jungbluth AA, Huang HJ, Cavenee WK, Smyth FE, Hall CM, Watson N, Nice EC, Gullick WJ, Old LJ, Burgess AW, Scott AM.

Int J Cancer. 2002 Mar 20;98(3):398-408.

40.

Radiotherapy and cellular signalling.

Lewanski CR, Gullick WJ.

Lancet Oncol. 2001 Jun;2(6):366-70. Review. Erratum in: Lancet Oncol 2001 Jul;2(7):455.

PMID:
11905753
41.
42.

The Type 1 growth factor receptors and their ligands considered as a complex system.

Gullick WJ.

Endocr Relat Cancer. 2001 Jun;8(2):75-82. Review.

PMID:
11397665
43.

Intracellular expression of the truncated extracellular domain of c-erbB-3/HER3.

Srinivasan R, Leverton KE, Sheldon H, Hurst HC, Sarraf C, Gullick WJ.

Cell Signal. 2001 May;13(5):321-30.

PMID:
11369513
45.

Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer.

Gilmour LM, Macleod KG, McCaig A, Gullick WJ, Smyth JF, Langdon SP.

Cancer Res. 2001 Mar 1;61(5):2169-76.

46.

The EGF-CFC family: novel epidermal growth factor-related proteins in development and cancer.

Saloman DS, Bianco C, Ebert AD, Khan NI, De Santis M, Normanno N, Wechselberger C, Seno M, Williams K, Sanicola M, Foley S, Gullick WJ, Persico G.

Endocr Relat Cancer. 2000 Dec;7(4):199-226. Review.

PMID:
11174844
47.

Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers.

Srinivasan R, Gillett CE, Barnes DM, Gullick WJ.

Cancer Res. 2000 Mar 15;60(6):1483-7.

48.

Assessment of HER2 status in breast cancer: why, when and how?

Dowsett M, Cooke T, Ellis I, Gullick WJ, Gusterson B, Mallon E, Walker R.

Eur J Cancer. 2000 Jan;36(2):170-6. Review.

PMID:
10741274
49.

c-erbB-4 protein expression in human breast cancer.

Kew TY, Bell JA, Pinder SE, Denley H, Srinivasan R, Gullick WJ, Nicholson RI, Blamey RW, Ellis IO.

Br J Cancer. 2000 Mar;82(6):1163-70.

Supplemental Content

Loading ...
Support Center